Aditxt Inc. (NASDAQ: ADTX), a leader in advancing health technologies through its social innovation platform, has announced a significant milestone for its subsidiary, Pearsanta, Inc. Pearsanta has been invited to submit a full proposal for the U.S. Department of Defense’s OCRP Pilot Award, focusing on the Mitomic(R) Ovarian Test (MOT(TM)). This novel blood-based diagnostic aims to detect ovarian cancer at an early stage, a critical factor in improving survival rates.
The invitation follows a favorable review of Pearsanta’s pre-proposal, highlighting the scientific merit and innovation of the MOT(TM). If awarded, the grant could provide up to $350,000 over two years to support a multi-center clinical study aimed at validating the test and preparing for its commercial launch as a laboratory-developed test. This development represents a promising step forward in the fight against ovarian cancer, a disease often diagnosed at a late stage due to the lack of early detection methods.
The potential impact of this diagnostic tool on women's health cannot be overstated. Early detection of ovarian cancer significantly increases the chances of successful treatment and survival. The MOT(TM) could fill a critical gap in women's healthcare, offering a non-invasive, accessible option for early detection. The involvement of the U.S. Department of Defense underscores the importance of this initiative, not only for military personnel and their families but for women worldwide.
Aditxt’s commitment to advancing health technologies through collaborative innovation is evident in this endeavor. By leveraging its ecosystem of research institutions, industry partners, and shareholders, Aditxt aims to address some of the most pressing health challenges. The progress of Pearsanta’s MOT(TM) is a testament to the potential of Aditxt’s model to bring transformative health solutions to market.
For more information on Aditxt Inc. and its initiatives, visit https://www.Aditxt.com.
